BRIEF-TG Therapeutics Announces Publication Of Results From The UNITY-NHL Phase 2b Trial
BRIEF-TG Therapeutics Announces Publication Of Results From The UNITY-NHL Phase 2b Trial
Brief-TG治疗公司宣布公布Unity-NHL 2b期试验的结果
March 9 (Reuters) - TG Therapeutics Inc :
* TG THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM THE UNITY-NHL PHASE 2B TRIAL EVALUATING UMBRALISIB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* TG THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM THE UNITY-NHL PHASE 2B TRIAL EVALUATING UMBRALISIB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 9 (Reuters) - TG Therapeutics Inc :
* TG THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM THE UNITY-NHL PHASE 2B TRIAL EVALUATING UMBRALISIB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月9日电-TG治疗公司：*TG治疗公司宣布在临床肿瘤学杂志上发表评估复发或难治性惰性非霍奇金淋巴瘤患者的UMBRALISIB单一疗法的Unity-NHL 2B期试验的结果Eikon的源文本：进一步的公司报道：(Reurs.Briefs@thomsonreurs.com；)
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧
点击这里分享给好友
暂无评论，快来抢沙发吧！